Neurosense Cash from 2010 to 2026
| NRSN Stock | USD 1.02 0.08 8.51% |
Cash | First Reported 2020-03-31 | Previous Quarter 666 K | Current Value 666 K | Quarterly Volatility 3.2 M |
Check Neurosense Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neurosense Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 2.2 K, Depreciation And Amortization of 18.8 K or Interest Expense of 373.3 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 12.14. Neurosense financial statements analysis is a perfect complement when working with Neurosense Therapeutics Valuation or Volatility modules.
Neurosense | Cash | Build AI portfolio with Neurosense Stock |
Evaluating Neurosense Therapeutics's Cash across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Neurosense Therapeutics's fundamental strength.
Latest Neurosense Therapeutics' Cash Growth Pattern
Below is the plot of the Cash of Neurosense Therapeutics over the last few years. Cash refers to the most liquid asset of Neurosense Therapeutics, which is listed under current asset account on Neurosense Therapeutics balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Neurosense Therapeutics customers. The amounts must be unrestricted with restricted cash listed in a different Neurosense Therapeutics account. It is the total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts. Neurosense Therapeutics' Cash historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Neurosense Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Cash | 10 Years Trend |
|
Cash |
| Timeline |
Neurosense Cash Regression Statistics
| Arithmetic Mean | 2,248,882 | |
| Geometric Mean | 1,522,922 | |
| Coefficient Of Variation | 115.27 | |
| Mean Deviation | 1,775,142 | |
| Median | 895,000 | |
| Standard Deviation | 2,592,390 | |
| Sample Variance | 6.7T | |
| Range | 10.4M | |
| R-Value | 0.53 | |
| Mean Square Error | 5.2T | |
| R-Squared | 0.28 | |
| Significance | 0.03 | |
| Slope | 271,278 | |
| Total Sum of Squares | 107.5T |
Neurosense Cash History
Other Fundumenentals of Neurosense Therapeutics
Neurosense Therapeutics Cash component correlations
Click cells to compare fundamentals
About Neurosense Therapeutics Financial Statements
Neurosense Therapeutics investors utilize fundamental indicators, such as Cash, to predict how Neurosense Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Pair Trading with Neurosense Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Neurosense Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neurosense Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Neurosense Stock
| 0.58 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.39 | KYTX | Kyverna Therapeutics | PairCorr |
| 0.37 | LRMR | Larimar Therapeutics | PairCorr |
| 0.36 | ENGN | enGene Holdings Common | PairCorr |
The ability to find closely correlated positions to Neurosense Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Neurosense Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Neurosense Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Neurosense Therapeutics to buy it.
The correlation of Neurosense Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Neurosense Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Neurosense Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Neurosense Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Neurosense Therapeutics Correlation against competitors. To learn how to invest in Neurosense Stock, please use our How to Invest in Neurosense Therapeutics guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Will Biotechnology sector continue expanding? Could Neurosense diversify its offerings? Factors like these will boost the valuation of Neurosense Therapeutics. Anticipated expansion of Neurosense directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Neurosense Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate Neurosense Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Neurosense Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Neurosense Therapeutics' market price to deviate significantly from intrinsic value.
It's important to distinguish between Neurosense Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Neurosense Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Neurosense Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.